The estimated Net Worth of Stephen Mayo is at least $542 Thousand dollars as of 5 March 2024. Stephen Mayo owns over 3,135 units of Allogene Therapeutics Inc stock worth over $19,267 and over the last 4 years Stephen sold ALLO stock worth over $522,691.
Stephen has made over 3 trades of the Allogene Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Stephen sold 3,135 units of ALLO stock worth $385,480 on 5 March 2024.
The largest trade Stephen's ever made was selling 10,000 units of Allogene Therapeutics Inc stock on 7 August 2023 worth over $42,900. On average, Stephen trades about 933 units every 32 days since 2021. As of 5 March 2024 Stephen still owns at least 6,621 units of Allogene Therapeutics Inc stock.
You can see the complete history of Stephen Mayo stock trades at the bottom of the page.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun, and Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: